JP6541875B2 - IgGFcドメインを有する融合タンパク質の安定な液状製剤 - Google Patents
IgGFcドメインを有する融合タンパク質の安定な液状製剤 Download PDFInfo
- Publication number
- JP6541875B2 JP6541875B2 JP2018517113A JP2018517113A JP6541875B2 JP 6541875 B2 JP6541875 B2 JP 6541875B2 JP 2018517113 A JP2018517113 A JP 2018517113A JP 2018517113 A JP2018517113 A JP 2018517113A JP 6541875 B2 JP6541875 B2 JP 6541875B2
- Authority
- JP
- Japan
- Prior art keywords
- domain
- histidine
- polysorbate
- sucrose
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
前述したように、既に提供されたアフリベルセプトのようなIgGFcドメインを有する融合タンパク質が安定化した製剤は、苛酷条件で安定性が顕著に減少する問題が発生するため、一般的な貯蔵条件だけでなく、苛酷条件でも前記融合タンパク質が安定に維持され得る製剤の開発が要求されている。
前記液状製剤の有効成分である融合タンパク質(fusion protein)において、血管内皮細胞増殖因子(VEGF)の可溶性細胞外ドメインは、第1のVEGF受容体の免疫グロブリン様ドメイン2と、第2のVEGF受容体の免疫グロブリン様ドメイン3とを含むことができ、ヒト免疫グロブリンG(IgG)のFcドメインは、IgG1、IgG2、IgG3またはIgG4のFcドメインであってもよく、好ましくは、IgG1のFcドメインであってもよい。ここで、Fc領域(Fc region)は、ヒンジ(hinge)−CH1−CH2−CH3で構成されており、CH1が欠失された形態であってもよい。
製剤における最適のpH条件の評価
本実施例1および以下の実施例2〜5では、先行技術文献である国際公開公報WO2007/149334号に開示された液状製剤を5±3℃で保管したものを対照群(1)にし、対照群(1)に苛酷条件(40℃以上の温度)を加えたものを対照群(2)にして、製剤安定性を本発明の多様な形態の液状製剤安定性と比較した。
製剤における最適の緩衝液条件の評価
本実施例では、抗−VEGF−Fc融合タンパク質であるアフリベルセプトを有効成分として含有する液状製剤の最適の緩衝液条件を確認するために次のように試料を製造した。
製剤における最適の糖種類条件の評価
本実施例では、抗−VEGF−Fc融合タンパク質であるアフリベルセプトを有効成分として含有する液状製剤の最適の糖を確認するために、次のように試料を製造した。
製剤における最適の糖濃度条件の評価
本実施例は、抗−VEGF−Fc融合タンパク質であるアフリベルセプトを有効成分として含有する液状製剤の最適の糖濃度を確認するために、次のように試料を製造した。
さらなる塩条件の評価
本実施例では、抗−VEGF−Fc融合タンパク質であるアフリベルセプトを有効成分として含有する液状製剤の最適のさらなる塩成分を確認するために、次のように試料を製造した。
撹拌条件で界面活性剤の有無による安定性の評価
本実施例では、抗−VEGF−Fc融合タンパク質であるアフリベルセプトを有効成分として含有するヒスチジン−HCl緩衝液ベースの液状製剤で撹拌をする間に、スクロース濃度およびポリソルベート20の有無による製剤安定性を評価するために、次のように試料を製造した。
製剤における最適のポリソルベート20濃度条件の評価
本実施例では、抗−VEGF−Fc融合タンパク質であるアフリベルセプトを有効成分として含有する液状製剤の最適のポリソルベート20の濃度を確認するために、次のように試料を製造した。
Claims (6)
- 血管内皮細胞増殖因子(Vascular Endothelial Growth Factor、VEGF)受容体の可溶性細胞外ドメインとヒト免疫グロブリンG(IgG)のFcドメインが融合された、10〜100mg/mLのタンパク質と;
ヒスチジン塩を含み、5.7〜6.2のpH範囲を有する緩衝液と;
2.5%〜10%のスクロース、トレハロース、マンニトールおよびグルコースからなる群から選ばれる糖と;
0%〜0.1%のポリソルベート20およびポリソルベート80からなる群から選ばれる界面活性剤と;
を含み、前記VEGF受容体の可溶性細胞外ドメインは、第1のVEGF受容体の免疫グロブリン様ドメイン2と、第2のVEGF受容体の免疫グロブリン様ドメイン3とを含み、前記ヒスチジン塩は、10mM〜50mMのヒスチジン−HClまたはヒスチジン−アセテートであることを特徴とする、液状製剤。 - 前記糖は、5%〜10%のスクロースであることを特徴とする、請求項1に記載の液状製剤。
- ヒスチジン塩を含み、5.7〜6.2のpH範囲を有する緩衝液と;
糖および界面活性剤からなる群から選ばれた一つまたはそれ以上の安定化剤と;を含み、
前記ヒスチジン塩は、10mM〜50mMのヒスチジン−HClまたはヒスチジン−アセテートであり、前記糖は、2.5%〜10%のスクロース、トレハロース、マンニトールおよびグルコースからなる群から選ばれたいずれか一つであり、前記界面活性剤は、0%〜0.1%のポリソルベート20またはポリソルベート80である、VEGF受容体の可溶性細胞外ドメインとIgGのFcドメインが融合されたタンパク質を含む液状製剤の安定化用組成物であって、前記VEGF受容体の可溶性細胞外ドメインは、第1のVEGF受容体の免疫グロブリン様ドメイン2と、第2のVEGF受容体の免疫グロブリン様ドメイン3とを含む、組成物。 - 前記界面活性剤は、0%〜0.03%のポリソルベート20またはポリソルベート80であることを特徴とする、請求項3に記載の組成物。
- 請求項3または4に記載のVEGF受容体の可溶性細胞外ドメインとIgGのFcドメインが融合されたタンパク質を含む液状製剤の安定化用組成物と;
アフリベルセプト(Aflibercept)と;を含む液状製剤。 - 硝子体内注射(intravitreal injection)に適合したものであることを特徴とする、請求項5に記載の液状製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150089186 | 2015-06-23 | ||
KR10-2015-0089186 | 2015-06-23 | ||
KR1020160078234A KR101808234B1 (ko) | 2015-06-23 | 2016-06-22 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
KR10-2016-0078234 | 2016-06-22 | ||
PCT/KR2016/006679 WO2016208989A1 (en) | 2015-06-23 | 2016-06-23 | A stable liquid formulation of fusion protein with igg fc domain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018517773A JP2018517773A (ja) | 2018-07-05 |
JP6541875B2 true JP6541875B2 (ja) | 2019-07-17 |
Family
ID=57810344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517113A Active JP6541875B2 (ja) | 2015-06-23 | 2016-06-23 | IgGFcドメインを有する融合タンパク質の安定な液状製剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9982032B2 (ja) |
EP (2) | EP3313373A4 (ja) |
JP (1) | JP6541875B2 (ja) |
KR (3) | KR101808234B1 (ja) |
CN (2) | CN107889457B (ja) |
AU (1) | AU2016283557B9 (ja) |
BR (1) | BR112017027945A2 (ja) |
CA (1) | CA2990582C (ja) |
MX (1) | MX2017016907A (ja) |
RU (1) | RU2688679C1 (ja) |
WO (1) | WO2016208989A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX370207B (es) | 2013-07-23 | 2019-12-05 | Novaliq Gmbh | Composiciones estabilizadas de anticuerpos. |
MX2018004695A (es) * | 2015-10-16 | 2019-03-14 | Regeneron Pharma | Composiciones de proteinas estables. |
CA3011638C (en) * | 2016-01-26 | 2023-01-10 | Formycon Ag | Liquid formulation of a vegf antagonist |
US11135266B2 (en) | 2016-11-21 | 2021-10-05 | Just-Evotec Biologics, Inc. | Aflibercept formulations and uses thereof |
KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
WO2019020777A1 (en) * | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
US20200255496A1 (en) | 2017-09-18 | 2020-08-13 | Amgen Inc. | Vegfr-fc fusion protein formulations |
MX2020005170A (es) * | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
EP3713591A1 (en) * | 2017-11-20 | 2020-09-30 | Just-Evotec Biologics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
WO2019124946A1 (ko) * | 2017-12-22 | 2019-06-27 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
WO2019173767A1 (en) * | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
WO2020055123A1 (ko) * | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
MX2021004774A (es) * | 2018-10-29 | 2021-08-24 | Hoffmann La Roche | Formulacion de anticuerpos. |
US20220143137A1 (en) | 2019-02-13 | 2022-05-12 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
KR20210077645A (ko) * | 2019-12-17 | 2021-06-25 | 주식회사 프로젠 | 신규 주사제 제형 |
EP3838260A1 (en) * | 2019-12-20 | 2021-06-23 | Ares Trading S.A. | Igg:tgf rii fusion protein composition |
CN115135302A (zh) * | 2019-12-20 | 2022-09-30 | 阿雷斯贸易股份有限公司 | IgG:TGFβRII融合蛋白组合物 |
KR102337471B1 (ko) * | 2019-12-23 | 2021-12-09 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형 |
JP2023535933A (ja) * | 2020-07-24 | 2023-08-22 | パンジェン バイオテック インコーポレイテッド | 眼科用液状組成物 |
US20230312683A1 (en) * | 2020-07-31 | 2023-10-05 | Celltrion Inc. | Stable pharmaceutical preparation |
CN114324882B (zh) * | 2020-10-12 | 2022-12-27 | 广东菲鹏生物有限公司 | 蛋白稳定剂及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ZA200708845B (en) * | 2005-03-25 | 2010-07-28 | Regeneron Pharma | Vegf antogonist formulations |
JP5216002B2 (ja) | 2006-06-16 | 2013-06-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 硝子体内投与に適したvegfアンタゴニスト製剤 |
KR20130096731A (ko) * | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가,확인 또는 진화시키는 방법 |
KR101698386B1 (ko) * | 2010-10-06 | 2017-02-01 | 엘지디스플레이 주식회사 | 편광기능이 구비된 컬러필터층을 구비한 액정표시장치 및 이의 제조 방법 |
SG10201802789VA (en) * | 2011-01-13 | 2018-05-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
EP2660251A1 (en) * | 2012-04-30 | 2013-11-06 | Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca | Antibodies or fragments thereof against hemopexin for use in the treatment of ocular diseases |
US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
EP2919812A4 (en) * | 2012-11-19 | 2016-05-18 | Merck Sharp & Dohme | Liquid formulations for TNFR: FC fusion proteins |
CN110193009A (zh) * | 2013-07-12 | 2019-09-03 | 伊维希比奥公司 | 用于治疗或预防眼科病的方法 |
CA2925416A1 (en) * | 2013-09-27 | 2015-04-02 | Hanmi Pharm. Co., Ltd. | Sustained type human growth hormone preparation |
ES2875878T3 (es) * | 2013-11-18 | 2021-11-11 | Formycon Ag | Composición farmacéutica de un anticuerpo anti-VEGF |
US9700595B2 (en) * | 2013-11-29 | 2017-07-11 | Ares Trading Sa | Liquid formulation of a fusion protein comprising TNFR and Fc region |
-
2016
- 2016-06-22 KR KR1020160078234A patent/KR101808234B1/ko active IP Right Grant
- 2016-06-23 BR BR112017027945-2A patent/BR112017027945A2/pt active Search and Examination
- 2016-06-23 AU AU2016283557A patent/AU2016283557B9/en active Active
- 2016-06-23 CN CN201680036177.4A patent/CN107889457B/zh active Active
- 2016-06-23 EP EP16814702.3A patent/EP3313373A4/en active Pending
- 2016-06-23 US US15/190,378 patent/US9982032B2/en active Active
- 2016-06-23 RU RU2018102318A patent/RU2688679C1/ru active
- 2016-06-23 WO PCT/KR2016/006679 patent/WO2016208989A1/en active Application Filing
- 2016-06-23 EP EP20195634.9A patent/EP3824879A1/en active Pending
- 2016-06-23 CA CA2990582A patent/CA2990582C/en active Active
- 2016-06-23 JP JP2018517113A patent/JP6541875B2/ja active Active
- 2016-06-23 CN CN202111260492.4A patent/CN114159386A/zh active Pending
- 2016-06-23 MX MX2017016907A patent/MX2017016907A/es unknown
-
2017
- 2017-12-06 KR KR1020170166663A patent/KR20170138387A/ko not_active IP Right Cessation
-
2022
- 2022-09-08 KR KR1020220114104A patent/KR20220130053A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3313373A1 (en) | 2018-05-02 |
KR20170000356A (ko) | 2017-01-02 |
US9982032B2 (en) | 2018-05-29 |
BR112017027945A2 (pt) | 2018-08-28 |
KR101808234B1 (ko) | 2017-12-12 |
MX2017016907A (es) | 2018-04-18 |
RU2688679C1 (ru) | 2019-05-22 |
CN107889457B (zh) | 2021-11-12 |
CN107889457A (zh) | 2018-04-06 |
KR20220130053A (ko) | 2022-09-26 |
CA2990582A1 (en) | 2016-12-29 |
WO2016208989A1 (en) | 2016-12-29 |
AU2016283557A1 (en) | 2017-12-14 |
CN114159386A (zh) | 2022-03-11 |
EP3313373A4 (en) | 2019-03-20 |
US20160376342A1 (en) | 2016-12-29 |
JP2018517773A (ja) | 2018-07-05 |
KR20170138387A (ko) | 2017-12-15 |
CA2990582C (en) | 2020-06-09 |
AU2016283557B2 (en) | 2020-04-09 |
EP3824879A1 (en) | 2021-05-26 |
AU2016283557B9 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6541875B2 (ja) | IgGFcドメインを有する融合タンパク質の安定な液状製剤 | |
AU2020220210B2 (en) | Methods for treating ocular diseases | |
AU2021286278B2 (en) | Methods for treating ocular diseases | |
US10568951B2 (en) | Pharmaceutical composition of an anti-VEGF antibody | |
KR20220062279A (ko) | 안질환의 치료 방법 | |
RU2776850C2 (ru) | Способы лечения глазных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190517 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190603 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190611 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6541875 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |